FLAM
First Light Asset Management Portfolio holdings
AUM
$771M
This Quarter Return
+10.54%
1 Year Return
+33.17%
3 Year Return
+208.13%
5 Year Return
+426.73%
10 Year Return
+3,318.8%
AUM
$1.51B
AUM Growth
+$1.51B
(+12%)
Cap. Flow
+$131M
Cap. Flow
% of AUM
8.7%
Top 10 Holdings %
Top 10 Hldgs %
43.35%
Holding
93
New
19
Increased
39
Reduced
13
Closed
16
Top Buys
| 1 |
CUTR
Cutera, Inc.
CUTR
|
$37.4M |
| 2 |
Aldeyra Therapeutics
ALDX
|
$31.2M |
| 3 |
Sutro Biopharma
STRO
|
$28M |
| 4 |
NeoGenomics
NEO
|
$23.4M |
| 5 |
Tandem Diabetes Care
TNDM
|
$22.8M |
Top Sells
| 1 |
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
|
$86.4M |
| 2 |
CareDx
CDNA
|
$39.1M |
| 3 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$26.6M |
| 4 |
Halozyme
HALO
|
$23.4M |
| 5 |
Glaukos
GKOS
|
$12.2M |
Sector Composition
| 1 | Healthcare | 84.27% |
| 2 | Communication Services | 4.55% |
| 3 | Energy | 0.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
908 Devices
MASS
$199M
| $1M | 0.07% |
20,700
-59,300
| -74% | -$2.88M |
|
52
AbbVie
ABBV
$374B
| $647K | 0.04% |
5,981
| – | – |
|
53
Integer Holdings
ITGR
$3.71B
| $538K | 0.04% |
+5,846
| New | +$538K |
|
|
NUVA
54
DELISTED
NuVasive, Inc.
NUVA
| $515K | 0.03% |
7,850
+2,622
| +50% | +$172K |
|
55
Baxter International
BAX
$12.1B
| $500K | 0.03% |
5,929
+2,671
| +82% | +$225K |
|
56
Envista
NVST
$3.37B
| $481K | 0.03% |
11,793
+2,808
| +31% | +$115K |
|
|
HRC
57
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $480K | 0.03% |
4,346
+2,225
| +105% | +$246K |
|
58
Cigna
CI
$80.2B
| $470K | 0.03% |
1,943
+383
| +25% | +$92.6K |
|
59
Bristol-Myers Squibb
BMY
$96.7B
| $458K | 0.03% |
+7,256
| New | +$458K |
|
60
GSK
GSK
$79.3B
| $449K | 0.03% |
+12,574
| New | +$449K |
|
61
Elevance Health
ELV
$72.4B
| $447K | 0.03% |
1,244
| – | – |
|
62
Waters Corp
WAT
$17.3B
| $436K | 0.03% |
+1,536
| New | +$436K |
|
|
SYNH
63
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $435K | 0.03% |
5,736
+1,267
| +28% | +$96.1K |
|
64
Hologic
HOLX
$14.7B
| $435K | 0.03% |
5,845
+2,505
| +75% | +$186K |
|
65
Gilead Sciences
GILD
$140B
| $433K | 0.03% |
6,705
+1,530
| +30% | +$98.8K |
|
66
Avantor
AVTR
$8.74B
| $422K | 0.03% |
+14,596
| New | +$422K |
|
67
ICU Medical
ICUI
$3.06B
| $419K | 0.03% |
2,039
+998
| +96% | +$205K |
|
68
CVS Health
CVS
$93B
| $415K | 0.03% |
5,519
+1,337
| +32% | +$101K |
|
69
United Therapeutics
UTHR
$17.7B
| $412K | 0.03% |
+2,466
| New | +$412K |
|
70
Becton Dickinson
BDX
$54.3B
| $404K | 0.03% |
1,662
| – | – |
|
71
Emergent Biosolutions
EBS
$418M
| $399K | 0.03% |
+4,294
| New | +$399K |
|
72
Perrigo
PRGO
$3.21B
| $398K | 0.03% |
9,823
+4,548
| +86% | +$184K |
|
73
Johnson & Johnson
JNJ
$429B
| $355K | 0.02% |
2,161
| – | – |
|
74
Sanofi
SNY
$122B
| $329K | 0.02% |
6,650
| – | – |
|
75
Pfizer
PFE
$141B
| $307K | 0.02% |
8,469
| – | – |
|